Your browser is no longer supported. Please, upgrade your browser.
Settings
ACHN Achillion Pharmaceuticals, Inc. daily Stock Chart
ACHN [NASD]
Achillion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own0.15% Shs Outstand138.73M Perf Week-8.20%
Market Cap388.44M Forward P/E- EPS next Y-0.78 Insider Trans0.00% Shs Float138.52M Perf Month-12.50%
Income-68.60M PEG- EPS next Q-0.15 Inst Own84.00% Short Float6.39% Perf Quarter13.36%
Sales- P/S- EPS this Y18.30% Inst Trans7.03% Short Ratio5.68 Perf Half Y-2.78%
Book/sh1.79 P/B1.56 EPS next Y-23.80% ROA-24.20% Target Price4.17 Perf Year-23.50%
Cash/sh1.83 P/C1.53 EPS next 5Y17.58% ROE-25.20% 52W Range1.29 - 3.98 Perf YTD76.10%
Dividend- P/FCF- EPS past 5Y4.10% ROI- 52W High-29.65% Beta2.39
Dividend %- Quick Ratio19.70 Sales past 5Y- Gross Margin- 52W Low117.05% ATR0.19
Employees56 Current Ratio19.70 Sales Q/Q- Oper. Margin- RSI (14)42.79 Volatility7.14% 6.37%
OptionableYes Debt/Eq0.00 EPS Q/Q8.40% Profit Margin- Rel Volume0.70 Prev Close2.87
ShortableYes LT Debt/Eq0.00 EarningsMay 08 Payout- Avg Volume1.56M Price2.80
Recom2.30 SMA20-5.55% SMA50-7.74% SMA200-0.03% Volume1,089,845 Change-2.44%
May-21-18Upgrade Barclays Underweight → Equal Weight $5
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3.50
Sep-12-17Reiterated Ladenburg Thalmann Buy $9 → $6.50
Aug-10-17Downgrade Robert W. Baird Outperform → Neutral $5
Aug-09-17Reiterated Chardan Capital Markets Neutral $5 → $4
May-18-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-02-17Initiated Ladenburg Thalmann Buy $10
Nov-04-16Upgrade Chardan Capital Markets Sell → Neutral $5
Sep-23-16Reiterated Chardan Capital Markets Sell $4 → $5
Sep-23-16Initiated Wedbush Outperform $13
Sep-15-16Initiated FBR & Co. Outperform $16
Jul-14-16Initiated Chardan Capital Markets Sell $4
Jul-07-16Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-26-16Upgrade Robert W. Baird Neutral → Outperform $10
Feb-25-16Reiterated Maxim Group Buy $11 → $8
Sep-09-15Initiated Jefferies Hold
Aug-13-15Reiterated Maxim Group Buy $19 → $11
May-20-15Reiterated Leerink Partners Outperform $25 → $16
May-20-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-10-15Reiterated Maxim Group Buy $22 → $19
May-17-19 08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
07:00AM  Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting GlobeNewswire
May-14-19 06:00AM  Achillion Granted Twentieth Patent for Factor D Portfolio GlobeNewswire +7.66%
May-13-19 09:13AM  Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1 Zacks -5.84%
May-11-19 08:40AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
May-09-19 04:00PM  What You Need to Know About Achillion Pharmaceuticals' Q1 Update Motley Fool
10:19AM  Achillion: 1Q Earnings Snapshot Associated Press
06:00AM  Achillion Reports First Quarter 2019 Financial Results GlobeNewswire
May-02-19 06:00AM  Biotech Bets and a Goodbye from a Favorite Expert MoneyShow
Apr-06-19 09:30AM  Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report? Zacks
Apr-04-19 10:23AM  Achillion Meets Enrollment Target in Kidney Disease Studies Zacks
Apr-03-19 12:50PM  Why Achillion Pharmaceuticals Stock Is Jumping Today Motley Fool
06:00AM  Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy GlobeNewswire
Mar-28-19 04:41PM  Achillion Completes Enrollment in Rare Blood Disorder Study Zacks
Mar-27-19 06:00AM  Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial GlobeNewswire
Mar-13-19 01:09PM  Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Mar-08-19 10:04AM  Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4 Zacks
06:00AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-07-19 06:00AM  Achillion Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-21-19 12:57PM  Why a Connecticut pharma firm moved its C-suite to Blue Bell American City Business Journals
06:00AM  Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market GlobeNewswire
Feb-19-19 06:00AM  Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference GlobeNewswire
Feb-12-19 07:50AM  Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-11-19 06:00AM  Achillion Appoints Brian Di Donato as Chief Financial Officer GlobeNewswire
Feb-04-19 12:45PM  Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
Jan-31-19 06:00AM  Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers GlobeNewswire
Jan-29-19 11:10AM  Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Jan-10-19 10:49AM  Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December Motley Fool
05:00AM  Top Picks 2019- Achillian Pharmaceuticals ACHN MoneyShow
Jan-03-19 07:36AM  The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen Benzinga
06:00AM  Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors GlobeNewswire
Dec-31-18 10:50AM  4 Healthcare Stocks That Are Raising Eyebrows ACCESSWIRE +7.43%
Dec-20-18 04:30PM  Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day Motley Fool -19.51%
Dec-19-18 03:45PM  Why Achillion Pharmaceuticals Sank Again Today Motley Fool -15.90%
Dec-18-18 05:32PM  Achillion Reports Positive Interim Data on Factor D Inhibitors Zacks -18.75%
04:33PM  Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today Motley Fool
03:02PM  Why Achillion Pharmaceuticals Is Cratering Again Today Motley Fool
08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga
06:50AM  Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals ACCESSWIRE
Dec-17-18 04:33PM  Why Achillion Pharmaceuticals Crashed Today Motley Fool -22.83%
04:02PM  Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update GlobeNewswire
Dec-16-18 02:18PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-12-18 01:15AM  Should You Buy Achillion Pharmaceuticals, Inc. (ACHN)? Insider Monkey
Dec-10-18 06:00AM  Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018 GlobeNewswire
Dec-08-18 06:19PM  RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
Dec-03-18 09:00AM  Implied Volatility Surging for Achillion (ACHN) Stock Options Zacks +7.96%
Nov-07-18 06:30AM  Achillion: 3Q Earnings Snapshot Associated Press
06:00AM  Achillion Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-18-18 01:14PM  Does Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Have A Volatile Share Price? Simply Wall St.
Oct-17-18 07:40AM  Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries Discovering Underlying Factors of Influence GlobeNewswire
Sep-25-18 06:00AM  Achillion to Present at the Leerink Partners Roundtable Series GlobeNewswire
Sep-14-18 09:09AM  The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion Zacks
Sep-13-18 09:14AM  IPOs and Foreign Investment Propel Biotech: 4 Top Picks Zacks
Sep-10-18 06:00AM  Achillion Appoints Paul Firuta Chief Operating Officer GlobeNewswire
Sep-07-18 09:30AM  Why Is Achillion (ACHN) Up 24.7% Since Last Earnings Report? Zacks
Aug-31-18 04:14AM  Achillion Pharmaceuticals (ACHN) Shares March Higher, Can It Continue? Zacks +8.49%
Aug-30-18 06:00AM  Achillion to Present at the Baird 2018 Global Healthcare Conference GlobeNewswire
Aug-23-18 11:39AM  7 Cheap Biotech Stocks to Buy Now InvestorPlace
Aug-20-18 08:20AM  Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-15-18 04:05PM  Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer GlobeNewswire
Aug-08-18 07:30PM  Achillion: 2Q Earnings Snapshot Associated Press
04:05PM  Achillion Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-11-18 11:05AM  Achillion's 3rd Factor D Inhibitor Enters Clinical Studies Zacks
Jul-10-18 06:05AM  Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D GlobeNewswire
Jul-02-18 07:05AM  Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-22-18 08:18AM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc. Motley Fool
Jun-14-18 06:05AM  Achillion to Present at the 2018 JMP Securities Life Sciences Conference GlobeNewswire
Jun-01-18 10:40AM  Achillion (ACHN) Down 6% Since Earnings Report: Can It Rebound? Zacks
07:30AM  Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol Discovering Underlying Factors of Influence GlobeNewswire
07:20AM  Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks ACCESSWIRE
May-31-18 08:32AM  Achillion Pharmaceuticals (ACHN): Moving Average Crossover Alert Zacks
May-21-18 01:56PM  SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion Benzinga
07:40AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
May-11-18 06:05AM  Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress GlobeNewswire
May-04-18 07:35AM  Wired News -Esperion Reported Positive Top-line Results from Late Stage Safety Study of its Cholestrol Drug - Bempedoic Acid ACCESSWIRE
06:35AM  Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
May-03-18 10:27AM  Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO Zacks
May-02-18 09:09AM  Achillion: 1Q Earnings Snapshot Associated Press
06:35AM  Achillion Reports First Quarter 2018 Financial Results and Management Transition GlobeNewswire
Apr-09-18 08:30AM  Investor Expectations to Drive Momentum within Credicorp, Essent Group, Achillion Pharmaceuticals, Banco Santander, S.A, Check Point Software Technologies, and Fomento Economico Mexicano S.A.B. de C.V Discovering Underlying Factors of Influence GlobeNewswire
Mar-20-18 08:37AM  Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock? Zacks
Mar-14-18 02:58PM  Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now Insider Monkey
Mar-13-18 07:35AM  Report: Developing Opportunities within Mimecast, Mazor Robotics, JD, Achillion Pharmaceuticals, Kulicke and Soffa Industries, and Weibo Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-08-18 06:05AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire +7.80%
Mar-05-18 07:00AM  Groupon Inc (GRPN), Globalstar, Inc. (GSAT) & More: Five Cheap Stocks to Buy Now Insider Monkey
Mar-01-18 12:16PM  [$$] Big Biotech Buys: Vericel, Achillion, PTC, Dicerna Barrons.com
Feb-28-18 06:05AM  Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G Initiative as Part of Rare Disease Day 2018 GlobeNewswire -5.52%
Feb-27-18 08:44AM  Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session Zacks
08:30AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Novavax ACCESSWIRE
07:40AM  Wired News Bellicum Pharma Shares Update On Clinical Hold of BPX-501 Studies in the US ACCESSWIRE
Feb-26-18 06:14PM  Why Achillion Pharmaceuticals, Inc. Stock Spiked Today Motley Fool +15.40%
08:20AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga
06:05AM  Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy GlobeNewswire
Feb-23-18 09:19AM  Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost Zacks
Feb-22-18 12:43PM  Was Achillion Pharmaceuticals Incs (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St.
06:21AM  Achillion reports 4Q loss Associated Press
06:05AM  Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-09-18 06:05AM  Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Dec-28-17 09:45AM  Actinium Posts Positive DMC View on Lomab-B Phase III Trial Zacks
Dec-27-17 11:29AM  Insys' Cannabidiol Gets Fast Track Designation in the U.S. Zacks
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scheer DavidDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:24 PM
VAN NOSTRAND ROBERT LDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:22 PM
FISHERMAN JASON SDirectorJun 06Option Exercise1.0520,00021,00070,000Jun 08 04:15 PM